ALIMERA SCIENCES, INC.

Analyst Reco. Alimera Sciences, Inc.

Equities

ALIM

US0162592028

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
3.555 ^USD	+5.18%		-2.60%	-17.71%

25/03	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT
19/03	Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	25/03	MT
Alliance Global Partners Upgrades Alimera Sciences to Buy From Neutral, Adjusts Price Target to $8 From $4.50	12/23/12	MT
HC Wainwright Adjusts Price Target on Alimera Sciences to $5 From $9, Keeps Buy Rating	19/23/19	MT
Alliance Global Partners Downgrades Alimera Sciences to Neutral Rating From Buy, Adjusts Price Target to $4.50 From $11	21/22/21	MT
HC Wainwright Adjusts Price Target on Alimera Sciences to $9 From $8, Reiterates Buy Rating	28/22/28	MT
HC Wainwright Adjusts Alimera Sciences' Price Target to $8 from $10, Keeps Buy Rating	10/22/10	MT
HC Wainwright Adjusts Alimera Sciences Price Target to $10 From $12, Maintains Buy Rating	25/22/25	MT
ALIMERA SCIENCES : Alliance Global Partners Adjusts Alimera Sciences PT to $14.50 From $16.50, Maintains Buy Rating	17/21/17	MT
ALIMERA SCIENCES : HC Wainwright Adjusts Alimera Sciences PT to $12 From $16, Maintains Buy Rating	16/21/16	MT
ALIMERA SCIENCES : HC Wainwright Adjusts Alimera Sciences' Price Target to $16 From $14, Maintains Buy Rating	15/21/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW